

FIRST LIGHT

RESEARCH

Mindtree | Target: Rs 2,180 | +5% | ADD

Continued recovery in travel; TCV robust

HDFC Bank | Target: Rs 1,800 | +26% | BUY

Asset quality stable despite NPA recognition

Banking | Q4FY21 Preview

NPA recognition begins; provision buffers to cushion earnings

SUMMARY

Mindtree

Mindtree (MTCL) reported a strong Q4FY21 performance with dollar revenue growth of 5.2% QoQ, ahead of estimates. EBIT margin was in line at 18.6% (-100bps QoQ). Deal wins were healthy, rising 20% QoQ to US\$ 375mn.

Management expects double-digit growth and a 20%+ EBITDA margin for FY22. We raise FY22/FY23 EPS by 14% each on better growth and margin assumptions. Rolling valuations over, we have a revised Mar'22 TP of Rs 2,180 (vs. Rs 1,850), based on an unchanged target P/E of 23.4x. Retain ADD.

[Click here for the full report.](#)

HDFC Bank

HDFC Bank's (HDFCB) Q4FY21 PAT was in line at Rs 82bn (+18% YoY) and asset quality was stable with GNPA ratio at ~1.3% despite the SC vacating its stay on NPA recognition. The restructured book was manageable at Rs 65bn (0.6% of loans). The bank has an adequate provision buffer and the Rs 13bn contingent provision made in Q4 is precautionary. Retail demand resolution and bounce rates have been improving steadily since Oct'20 and retail asset traction is returning to pre-Covid levels. Maintain BUY, Mar'22 TP unchanged at Rs 1,800.

[Click here for the full report.](#)

TOP PICKS

LARGE-CAP IDEAS

Company	Rating	Target
Cipla	Buy	1,000
TCS	Buy	3,780
Tech Mahindra	Buy	1,130

MID-CAP IDEAS

Company	Rating	Target
Alkem Labs	Buy	3,750
Greenply Industries	Buy	195
Laurus Labs	Buy	480
Transport Corp	Buy	330

Source: BOBCAPS Research

DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.58	(6bps)	(3bps)	95bps
India 10Y yield (%)	6.13	12bps	(7bps)	(31bps)
USD/INR	74.93	0.2	(3.4)	2.4
Brent Crude (US\$/bbl)	66.94	0.5	(2.8)	140.6
Dow	34,036	0.9	3.3	44.6
Shanghai	3,399	(0.5)	(0.6)	20.5
Sensex	48,804	0.5	(3.2)	59.5
India FII (US\$ mn)	12Apr	MTD	CYTD	FYTD
FII-D	46.1	(361.0)	(2,388.2)	(361.0)
FII-E	(331.6)	(287.2)	7,039.2	(287.2)

Source: Bank of Baroda Economics Research

BOBCAPS Research

research@bobcaps.in



Banking: Q4FY21 Preview

The SC has lifted its stay on tagging of NPAs but we expect slippages to be lower in Q4FY21 as banks have recognised a bulk of the Covid-related stress in their proforma numbers. Most players have created healthy provisioning buffers – this coupled with corporate resolutions should cushion earnings. Management commentary regarding the growth and asset quality effects of the second Covid wave will be keenly watched. We maintain our preference for frontline banks (ICICIBC, HDFCB, SBIN) as they are well provisioned and adequately capitalised.

[Click here for the full report.](#)

ADD

TP: Rs 2,180 | ▲ 5%

MINDTREE

| IT Services

| 16 April 2021

Continued recovery in travel; TCV robust

Mindtree (MTCL) reported a strong Q4FY21 performance with dollar revenue growth of 5.2% QoQ, ahead of estimates. EBIT margin was in line at 18.6% (-100bps QoQ). Deal wins were healthy, rising 20% QoQ to US\$ 375mn. Management expects double-digit growth and a 20%+ EBITDA margin for FY22. We raise FY22/FY23 EPS by 14% each on better growth and margin assumptions. Rolling valuations over, we have a revised Mar'22 TP of Rs 2,180 (vs. Rs 1,850), based on an unchanged target P/E of 23.4x. Retain ADD.

Ruchi Burde | Seema Nayak

research@bobcaps.in


Travel and manufacturing recovery continues: Despite seasonality, MTCL's dollar revenue increased 5.2% QoQ vs. 4.7% estimated. Sequential growth was driven by a 17% uptick in travel, media & services and a 9% uptick in manufacturing. Communications, media and technology grew at a healthy 4.1% QoQ. BFSI was flattish due to a few large deals being pushed to Q1FY22. Among geographies, Europe led the momentum at 8.6%. TCV at US\$ 375mn increased 20% QoQ. Overall, MTCL has delivered Q4 growth on par with tier-I IT players.

Ticker/Price	MTCL IN/Rs 2,070
Market cap	US\$ 4.6bn
Shares o/s	165mn
3M ADV	US\$ 30.0mn
52wk high/low	Rs 2,276/Rs 721
Promoter/FPI/DII	74%/11%/15%

Source: NSE

Margins steady: EBITDA margin stood at 21.9%, in line with management's guidance of achieving a 20%+ EBITDA margin for Q4. EBIT margin contracted 100bps QoQ to 18.6% due to salary hikes and a spike in hiring. Utilisation was at an all-time high of 84.3%, up 120bps QoQ. MTCL has embarked on a positive growth cycle following new CEO takeover, resulting in elevated margins due to an aggressive focus on profitable growth (using levers such as utilisation, offshoring and deep account mining).

STOCK PERFORMANCE



Source: NSE

Healthy pipeline; positive outlook: Per management, MTCL is on track to achieve double-digit growth in FY22 (already factored in our estimates), given its robust pipeline where a majority of the deals are annuity in nature. EBITDA margin is guided to hold above 20% in FY22.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21P	FY22E	FY23E
Total revenue (Rs mn)	70,215	77,643	79,678	97,011	110,247
EBITDA (Rs mn)	10,645	10,623	16,426	21,913	23,006
Adj. net profit (Rs mn)	7,542	6,309	11,103	14,627	15,257
Adj. EPS (Rs)	45.8	38.3	67.4	88.8	92.7
Adj. EPS growth (%)	32.1	(16.3)	76.0	31.7	4.3
Adj. ROAE (%)	24.9	19.5	29.7	31.3	28.0
Adj. P/E (x)	45.2	54.0	30.7	23.3	22.3
EV/EBITDA (x)	31.9	31.9	20.5	15.2	14.3

Source: Company, BOBCAPS Research



BUY

TP: Rs 1,800 | ▲ 26%

HDFC BANK

| Banking

| 17 April 2021

Asset quality stable despite NPA recognition

HDFC Bank's (HDFCB) Q4FY21 PAT was in line at Rs 82bn (+18% YoY) and asset quality was stable with GNPA ratio at ~1.3% despite the SC vacating its stay on NPA recognition. The restructured book was manageable at Rs 65bn (0.6% of loans). The bank has an adequate provision buffer and the Rs 13bn contingent provision made in Q4 is precautionary. Retail demand resolution and bounce rates have been improving steadily since Oct'20 and retail asset traction is returning to pre-Covid levels. Maintain BUY, Mar'22 TP unchanged at Rs 1,800.

Vikesh Mehta

research@bobcaps.in

Headline NPAs stable: HDFCB's GNPA ratio remained largely stable at 1.32% (proforma 1.38% in Q3) given that the slippage ratio stood at ~1.7% (vs. 1.8% in Q3). The bank used contingent provisions worth Rs 36bn towards these slippages and set aside a further Rs 5bn towards reversal of interest-on-interest, as per regulatory guidelines. NPAs in the wholesale book were marginal and a large portion of these may be upgraded once a Covid resolution plan is implemented.

Ticker/Price	HDFCB IN/Rs 1,429
Market cap	US\$ 105.5bn
Shares o/s	5,490mn
3M ADV	US\$ 205.5mn
52wk high/low	Rs 1,641/Rs 826
Promoter/FPI/DII	26%/37%/37%

Source: NSE

Retail demand resolution and cheque bounce rates improving: Retail demand resolution and cheque bounce rates continued to improve in Q4, though the latter has deteriorated marginally in April. States such as Maharashtra, Madhya Pradesh, Punjab and Telangana are showing higher stress. SME loans form ~20% of the overall portfolio and delinquency levels across buckets in this segment are now closer to pre-Covid levels.

STOCK PERFORMANCE



Source: NSE

Retail growth gradually picking up: Demand in the retail secured/unsecured segments has normalised with disbursements growing at 21% YoY/6% QoQ in Q4. Segments such as auto, housing and personal loans are showing good traction. The bank has disbursed loans worth Rs 265bn under ECLGS 1 & 2.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21P	FY22E	FY23E
Net interest income	482,432	561,863	648,796	765,703	920,305
NII growth (%)	20.3	16.5	15.5	18.0	20.2
Adj. net profit (Rs mn)	210,782	262,573	311,165	373,592	448,710
EPS (Rs)	39.6	48.0	56.6	67.8	81.4
P/E (x)	36.0	29.7	25.2	21.1	17.6
P/BV (x)	5.2	4.6	3.9	3.4	3.0
ROA (%)	1.8	1.9	1.9	2.0	2.0
ROE (%)	16.5	16.4	16.6	17.2	18.2

Source: Company, BOBCAPS Research | P – Provisional



NPA recognition begins; provision buffers to cushion earnings

The SC has lifted its stay on tagging of NPAs but we expect slippages to be lower in Q4FY21 as banks have recognised a bulk of the Covid-related stress in their proforma numbers. Most players have created healthy provisioning buffers – this coupled with corporate resolutions should cushion earnings. Management commentary regarding the growth and asset quality effects of the second Covid wave will be keenly watched. We maintain our preference for frontline banks (ICICIBC, HDFCB, SBIN) as they are well provisioned and adequately capitalised.

Vikesh Mehta

research@bobcaps.in

Pace of slippages likely to moderate: The Supreme Court recently lifted the standstill on NPA recognition, which implies better clarity on asset quality in Q4. Despite this, we expect the pace of incremental slippages to be lower QoQ as most of our coverage has recognised a bulk of the stress in their proforma numbers till Q3. Recovery from Bhushan Power and resolution of a few small cases should aid the sector. Credit cost is projected to be lower QoQ with large banks such as Axis Bank (AXSB) and ICICI (ICICIBC) potentially seeing writebacks of excess provisions. Variation in slippages from actual stress recognition and proforma reporting will be key monitorables. Fresh restructuring is likely to be negligible.

Loan growth yet to pick up meaningfully: As per RBI data, loan growth for the system remained sluggish at ~6% YoY in Q4. A large part of the growth was likely driven by retail and the emergency credit line scheme (ECLGS) while corporate growth remained negative. As per Q4 business updates provided by select banks, HDFC Bank (HDFCB) is the only outlier with a 14% YoY uptick in credit, Federal Bank (FB) grew 9%, and IndusInd (IIB) and RBL Bank (RBK) were largely flat. Deposit growth in the system stood at ~11% YoY in Q4 with HDFCB, IIB, Bandhan and RBK reporting healthy 10-14% QoQ growth in CASA deposits.

Interest reversals pose risk to NIM: A large float of CASA deposits is likely to provide tailwinds to margins but following the SC judgement, banks have to refund the interest-on-interest charged on overdue loans. Moreover, players that have not reversed interest on proforma NPAs but treated this under provisions run the risk of a one-off impact on NIM. Non-interest income is likely to be aided by QoQ improvement in fees and recoveries from written-off accounts. However, we expect treasury income to be lower as bond yields have risen ~30bps QoQ during the quarter.

RECOMMENDATION SNAPSHOT

Ticker	Price	Target	Rating
AUBANK IN	1,077	1,500	BUY
AXSB IN	669	760	BUY
BANDHAN IN	323	375	ADD
CBK IN	134	150	ADD
FB IN	76	85	ADD
HDFCB IN	1,428	1,800	BUY
ICICIBC IN	567	675	BUY
IDFCFB IN	54	23	SELL
IIB IN	865	1,100	BUY
KMB IN	1,766	2,100	BUY
RBK IN	188	195	SELL
SBIN IN	340	475	BUY

Price & Target in Rupees | Price as of 16 Apr 2021



Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

ADD – Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL – Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Rating distribution

As of 31 March 2021, out of 88 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 42 have BUY ratings, 13 have ADD ratings, 5 are rated REDUCE and 28 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such.

Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.